Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 1.71
(-0.29%)
SEK 1.71
(-0.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 11.21 Million SEK | 784.45% |
| 2022 | 1.26 Million SEK | 11436.11% |
| 2021 | -11.18 Thousand SEK | 4.98% |
| 2020 | -11.77 Thousand SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.03 Million SEK | 12147.91% |
| 2024 Q2 | 985.75 Thousand SEK | -67.49% |
| 2023 Q4 | 24.75 Thousand SEK | -99.69% |
| 2023 Q3 | 8.01 Million SEK | 353.33% |
| 2023 FY | 11.21 Million SEK | 784.45% |
| 2023 Q1 | 1.4 Million SEK | 168.6% |
| 2023 Q2 | 1.76 Million SEK | 25.58% |
| 2022 Q2 | -273.00 SEK | -100.07% |
| 2022 Q1 | 371.64 Thousand SEK | 15908.12% |
| 2022 FY | 1.26 Million SEK | 11436.11% |
| 2022 Q4 | 524.28 Thousand SEK | 40.66% |
| 2022 Q3 | 372.73 Thousand SEK | 136633.7% |
| 2021 Q3 | -2840.00 SEK | 3.57% |
| 2021 Q2 | -2945.00 SEK | 0.03% |
| 2021 FY | -11.18 Thousand SEK | 4.98% |
| 2021 Q1 | -2946.00 SEK | 0.0% |
| 2021 Q4 | -2351.00 SEK | 17.22% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | -11.77 Thousand SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 106.982% |
| Ziccum AB (publ) | -23.28 Million SEK | 148.176% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 96.761% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 73.154% |
| Mendus AB (publ) | 28.48 Million SEK | 60.62% |
| Genovis AB (publ.) | 54 Million SEK | 79.226% |
| Intervacc AB (publ) | -13.79 Million SEK | 181.327% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -416.734% |
| Active Biotech AB (publ) | -1.67 Million SEK | 769.748% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -12.599% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 58.173% |
| Aptahem AB (publ) | 2.63 Million SEK | -326.446% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 427.924% |
| Kancera AB (publ) | -1.96 Million SEK | 670.905% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -14469.204% |
| Fluicell AB (publ) | 1.73 Million SEK | -545.471% |
| Saniona AB (publ) | 11.78 Million SEK | 4.776% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 319.236% |
| Biovica International AB (publ) | 6.87 Million SEK | -63.128% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 148.182% |
| AcouSort AB (publ) | 8.38 Million SEK | -33.726% |
| Xintela AB (publ) | 78 Thousand SEK | -14282.419% |
| Abliva AB (publ) | -35.66 Million SEK | 131.456% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 107.637% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -299.654% |
| OncoZenge AB (publ) | 3000.00 SEK | -373842.9% |
| Amniotics AB (publ) | -1.93 Million SEK | 681.258% |
| 2cureX AB (publ) | -37.48 Million SEK | 129.926% |
| CombiGene AB (publ) | -21.29 Million SEK | 152.691% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 2752.077% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.007% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.29% |
| Corline Biomedical AB | 28.38 Million SEK | 60.471% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 109.14% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 132.597% |
| I-Tech AB | 27.56 Million SEK | 59.304% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 84.189% |
| Cyxone AB (publ) | 2.61 Million SEK | -329.655% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -229.659% |
| Biosergen AB | -456 Thousand SEK | 2560.151% |
| Cantargia AB (publ) | -3.45 Million SEK | 425.074% |
| NextCell Pharma AB | -43.74 Million SEK | 125.643% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 222.017% |
| Nanologica AB (publ) | -76 Thousand SEK | 14860.904% |
| SynAct Pharma AB | -778 Thousand SEK | 1541.939% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 5912.584% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 186.815% |
| Lipum AB (publ) | 53 Thousand SEK | -21066.579% |
| BioInvent International AB (publ) | 71.46 Million SEK | 84.302% |
| Alzinova AB (publ) | 19.87 Million SEK | 43.553% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 69.095% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -666.79% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 74888.58% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -576.616% |
| Simris Alg AB (publ) | 2 Million SEK | -458.958% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 413.36% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 68.299% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 1169.427% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -258.069% |